PerkinElmer Life Sciences

Bionas

Bionas GmbH
Friedrich-Barnewitz-Straße 3
18119 Rostock
Germany

Tel: +49 381 5196 244
Fax:
Email Us

Print Email to a friend

Bionas® specializes in instruments and services for label-free, cell-based assays.

The B2500 analyzing system is a 6 channel system for the simultaneous monitoring of oxygen consumption, acidification and cellular impedance/adhesion. The instrument generates real-time data about the metabolic activity of cells, including regeneration effects. Adherent, primary or suspension cells can be analyzed for applications in toxicology, oncology, drug discovery.

The B9600 adcon reader is a versatile instrument for label-free monitoring of cellular impedance in 96 well format. It provides real-time information about cell adhesion, proliferation, morphology etc. for high-throughput screening and laboratory research. GLP laboratory service is also available.

Further Information: http://www.bionas.de



Related news from our archive

Profiling of Tumor Tissue Slices is Awarded Prize
Novel drug screening tool based on the Bionas® 2500 analyzing system wins silver medal in European business plan contest.

Bionas Signs Service Contract with Solvay Pharmaceuticals
The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay´s obesity research program.

Bionas Raises € 2.1 M to Fund Marketing and Product Expansion
Bionas closes a financing deal to fund sales, marketing and product expansion, GENIUS Venture Capital GmbH and the KfW-Bankengruppe also participated in the financing.

Bionas Cell Profiling Device Selected by Solvay for Target Validation
Solvay selects the Bionas 2500 analyzing system to On-line monitoring of endothelial cell physiology.

Profiling of Tumor Tissue Slices is Awarded Prize
Novel drug screening tool based on the Bionas® 2500 analyzing system wins silver medal in European business plan contest.

Bionas Signs Service Contract with Solvay Pharmaceuticals
The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay´s obesity research program.

Bionas Raises € 2.1 M to Fund Marketing and Product Expansion
Bionas closes a financing deal to fund sales, marketing and product expansion, GENIUS Venture Capital GmbH and the KfW-Bankengruppe also participated in the financing.

Bionas Cell Profiling Device Selected by Solvay for Target Validation
Solvay selects the Bionas 2500 analyzing system to On-line monitoring of endothelial cell physiology.